AptaBio Therapeutics (Korea) Probability of Future Stock Price Finishing Over 8,302
| 293780 Stock | 6,570 20.00 0.30% |
AptaBio |
AptaBio Therapeutics Target Price Odds to finish over 8,302
The tendency of AptaBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 6,570 | 90 days | 6,570 | under 95 |
Based on a normal probability distribution, the odds of AptaBio Therapeutics to move above the current price in 90 days from now is under 95 (This AptaBio Therapeutics probability density function shows the probability of AptaBio Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon AptaBio Therapeutics has a beta of -0.59. This suggests as returns on the benchmark increase, returns on holding AptaBio Therapeutics are expected to decrease at a much lower rate. During a bear market, however, AptaBio Therapeutics is likely to outperform the market. Additionally AptaBio Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. AptaBio Therapeutics Price Density |
| Price |
Predictive Modules for AptaBio Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as AptaBio Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.AptaBio Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. AptaBio Therapeutics is not an exception. The market had few large corrections towards the AptaBio Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold AptaBio Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of AptaBio Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.35 | |
β | Beta against Dow Jones | -0.59 | |
σ | Overall volatility | 975.52 | |
Ir | Information ratio | -0.13 |
AptaBio Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AptaBio Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AptaBio Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| AptaBio Therapeutics generated a negative expected return over the last 90 days | |
| AptaBio Therapeutics has high historical volatility and very poor performance | |
| The company reported the revenue of 223.68 M. Net Loss for the year was (10.69 B) with profit before overhead, payroll, taxes, and interest of 336.97 M. | |
| AptaBio Therapeutics has accumulated about 6.57 B in cash with (8.9 B) of positive cash flow from operations. | |
| Roughly 34.0% of the company shares are owned by insiders or employees |
AptaBio Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AptaBio Stock often depends not only on the future outlook of the current and potential AptaBio Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AptaBio Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 22.2 M | |
| Cash And Short Term Investments | 22.9 B |
AptaBio Therapeutics Technical Analysis
AptaBio Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. AptaBio Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of AptaBio Therapeutics. In general, you should focus on analyzing AptaBio Stock price patterns and their correlations with different microeconomic environments and drivers.
AptaBio Therapeutics Predictive Forecast Models
AptaBio Therapeutics' time-series forecasting models is one of many AptaBio Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary AptaBio Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about AptaBio Therapeutics
Checking the ongoing alerts about AptaBio Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for AptaBio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| AptaBio Therapeutics generated a negative expected return over the last 90 days | |
| AptaBio Therapeutics has high historical volatility and very poor performance | |
| The company reported the revenue of 223.68 M. Net Loss for the year was (10.69 B) with profit before overhead, payroll, taxes, and interest of 336.97 M. | |
| AptaBio Therapeutics has accumulated about 6.57 B in cash with (8.9 B) of positive cash flow from operations. | |
| Roughly 34.0% of the company shares are owned by insiders or employees |
Other Information on Investing in AptaBio Stock
AptaBio Therapeutics financial ratios help investors to determine whether AptaBio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AptaBio with respect to the benefits of owning AptaBio Therapeutics security.